A qui tam lawsuit against a compounding pharmacy can start with someone inside the building: a pharmacist, a billing employee, or a sales representative who becomes a relator under the civil False Claims Act. These suits are filed under seal, so a pharmacy can be the subject of an active federal investigation for months without knowing a case exists. The exposure runs through records the pharmacy already generates every day: ingredient selection, compounding logs, and the claims submitted to Medicare, Medicaid, and TRICARE.
Who Files Qui Tam Suits Against Compounding Pharmacies
31 U.S.C. § 3730(b)(1) lets any person bring a civil action on the government's behalf, not only a competitor or a patient. In a compounding case, the relator can be someone who already had access to the pharmacy's internal records: a current or former pharmacist-in-charge, a compounding technician, a billing or reimbursement employee, or a sales representative paid on prescription volume. In one Middle District of Florida matter, Smart Pharmacy, Inc., SP2, LLC, and owner Gregory Balotin agreed in 2023 to pay at least $7.4 million after two former employees, in separate qui tam complaints filed years apart, alleged the pharmacy added the antipsychotic drug aripiprazole to compounded pain creams to boost reimbursement from Medicare Part D and TRICARE.
The Legal Theories Behind These Suits
Three theories recur in qui tam suits against compounding pharmacies. The first alleges kickbacks, payments to marketers, prescribers, or patients tied to prescription volume, which implicates the anti-kickback statute. The second alleges that the pharmacy billed federal programs for an ingredient added without a supportable clinical basis, inflating the per-prescription reimbursement. The third alleges that a compound was prepared or labeled in a way that misrepresented what the pharmacy actually dispensed. Each theory ties back to a claim the pharmacy submitted for payment, which is what makes it a False Claims Act matter rather than a board complaint. That is why the FDA and board due diligence that should accompany any acquisition has to look past the seller's current billing practices.
Why the Case Stays Sealed While the Pharmacy Keeps Operating
31 U.S.C. § 3730(b)(2) requires the relator to file the complaint in camera, under seal for at least 60 days, and bars service on the pharmacy until the court lifts the seal. 31 U.S.C. § 3730(b)(3) lets the government ask the court, for good cause, to extend that seal. During that window the pharmacy may still face a civil investigative demand or a grand jury subpoena tied to the same conduct. A civil investigative demand points to the civil track; a grand jury subpoena points to a parallel criminal inquiry. A pharmacy can receive either one without any indication that a relator's complaint already exists behind it.
A compounding pharmacy can receive a civil investigative demand or a grand jury subpoena with no indication that a sealed qui tam complaint is already pending behind it.
What Happens When the Government Decides Whether to Intervene
31 U.S.C. § 3730(b)(4) gives the government 60 days after receiving the complaint and the relator's supporting evidence to decide whether to intervene and take over the case, and that period extends along with any seal extension obtained under paragraph (3). If the government intervenes, it directs the litigation and the relator's share of any recovery falls between 15 and 25 percent under 31 U.S.C. § 3730(d)(1). If the government declines, the relator can still pursue the case alone, and the statutory share rises to between 25 and 30 percent under 31 U.S.C. § 3730(d)(2). A declination means the government chose not to run the case itself; the statute does not tie that choice to any evaluation of the case's merits, and the pharmacy remains a defendant in active litigation either way.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel upon receiving a civil investigative demand, a grand jury subpoena, or any other sign of a federal inquiry, even before a qui tam complaint is unsealed. Early legal intervention can protect the pharmacy's rights, help shape appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience. The firm defends compounding pharmacies named in qui tam complaints, from the sealed investigation forward. If your pharmacy received a civil investigative demand, a subpoena, or notice that a sealed complaint has been unsealed, contact us for a free, confidential consultation through our criminal healthcare fraud defense page.
